The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.
Acute Lymphoblastic Leukemia
BTCEs
Bispecific T-cell engagers
CAR-T
Hematological malignancies
Immunotherapy
T-ALL
Journal
Experimental hematology & oncology
ISSN: 2162-3619
Titre abrégé: Exp Hematol Oncol
Pays: England
ID NLM: 101590676
Informations de publication
Date de publication:
09 Jan 2023
09 Jan 2023
Historique:
received:
29
10
2022
accepted:
30
12
2022
entrez:
9
1
2023
pubmed:
10
1
2023
medline:
10
1
2023
Statut:
epublish
Résumé
T-cell acute lymphoblastic leukemia (T-ALL) is a challenging pediatric and adult haematologic disease still associated with an unsatisfactory cure rate. Unlike B-ALL, the availability of novel therapeutic options to definitively improve the life expectancy for relapsed/resistant patients is poor. Indeed, the shared expression of surface targets among normal and neoplastic T-cells still limits the efficacy and may induce fratricide effects, hampering the use of innovative immunotherapeutic strategies. However, novel monoclonal antibodies, bispecific T-cell engagers (BTCEs), and chimeric antigen receptors (CAR) T-cells recently showed encouraging results and some of them are in an advanced stage of pre-clinical development or are currently under investigation in clinical trials. Here, we review this exciting scenario focusing on most relevant advances, challenges, and perspectives of the emerging landscape of immunotherapy of T-cell malignancies.
Identifiants
pubmed: 36624522
doi: 10.1186/s40164-022-00368-w
pii: 10.1186/s40164-022-00368-w
pmc: PMC9828428
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5Subventions
Organisme : AIRC
ID : 21588
Informations de copyright
© 2023. The Author(s).
Références
Blood. 2007 Jun 1;109(11):4655-62
pubmed: 17311990
Blood Adv. 2021 Dec 14;5(23):5128-5139
pubmed: 34625791
Hum Gene Ther. 2023 Oct 20;:
pubmed: 37861302
J Immunol. 1998 Jun 15;160(12):5749-56
pubmed: 9637484
Int Immunol. 2009 Dec;21(12):1317-27
pubmed: 19819936
Am J Cancer Res. 2019 Jan 01;9(1):64-78
pubmed: 30755812
J Biotechnol. 2018 Oct 20;284:91-101
pubmed: 30142414
Immunology. 2018 Jun;154(2):196-203
pubmed: 29460282
Sci Transl Med. 2020 Mar 4;12(533):
pubmed: 32132216
Curr Drug Targets. 2006 Dec;7(12):1571-82
pubmed: 17168832
Nat Commun. 2022 Jul 26;13(1):4334
pubmed: 35882880
Blood Adv. 2018 Mar 13;2(5):517-528
pubmed: 29507075
J Biol Chem. 2002 Jan 4;277(1):13-22
pubmed: 11689561
Mol Ther. 2021 Sep 1;29(9):2707-2722
pubmed: 34274536
J Cell Physiol. 2019 May;234(5):5628-5642
pubmed: 30478951
Mol Cancer. 2019 Aug 20;18(1):125
pubmed: 31429760
Nat Immunol. 2016 Oct;17(10):1159-66
pubmed: 27548435
J Immunol. 2001 Apr 15;166(8):4931-42
pubmed: 11290771
J Clin Oncol. 2021 Oct 20;39(30):3340-3351
pubmed: 34324392
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Cancer Discov. 2016 Sep;6(9):972-85
pubmed: 27354269
Front Bioeng Biotechnol. 2020 Jun 25;8:678
pubmed: 32671047
Nat Med. 2006 Oct;12(10):1175-80
pubmed: 16998483
J Hematol Oncol. 2021 Mar 20;14(1):48
pubmed: 33743810
Br J Haematol. 2010 Sep;150(5):565-73
pubmed: 20629661
Leuk Lymphoma. 2019 Nov;60(11):2606-2621
pubmed: 31092071
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7172-7
pubmed: 8692964
Eur J Immunol. 2002 Sep;32(9):2532-42
pubmed: 12207337
Blood. 2020 Sep 10;136(11):1298-1302
pubmed: 32483610
Biomark Res. 2022 Feb 7;10(1):6
pubmed: 35130959
Physiol Rev. 2008 Jul;88(3):841-86
pubmed: 18626062
Int J Oncol. 2002 Apr;20(4):707-11
pubmed: 11894113
J Exp Clin Cancer Res. 2022 Jun 28;41(1):210
pubmed: 35765110
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Blood. 2018 Mar 1;131(9):995-999
pubmed: 29305553
Anticancer Drugs. 2020 Jun;31(5):536-539
pubmed: 31934889
J Clin Invest. 2017 Sep 1;127(9):3462-3471
pubmed: 28805662
Cancer. 2004 Sep 15;101(6):1414-9
pubmed: 15368329
Nat Immunol. 2013 Jul;14(7):741-8
pubmed: 23685786
Biochim Biophys Acta. 2007 Apr;1768(4):952-63
pubmed: 17169327
J Immunother Cancer. 2020 May;8(1):
pubmed: 32439800
Clin Cancer Res. 2017 Mar 1;23(5):1156-1166
pubmed: 27582488
Cancer Discov. 2012 Nov;2(11):1004-23
pubmed: 23107779
Bioconjug Chem. 2002 Jan-Feb;13(1):47-58
pubmed: 11792178
Trends Immunol. 2004 May;25(5):242-8
pubmed: 15099564
Signal Transduct Target Ther. 2022 Mar 22;7(1):93
pubmed: 35318309
Leuk Lymphoma. 2014 Mar;55(3):624-7
pubmed: 23937105
Leukemia. 2017 Oct;31(10):2151-2160
pubmed: 28074066
Stem Cell Rev Rep. 2020 Apr;16(2):369-384
pubmed: 32008159
Br J Haematol. 2008 Oct;143(2):153-68
pubmed: 18691165
Front Oncol. 2019 Mar 05;9:126
pubmed: 30891427
Clin Cancer Res. 2022 Jul 1;28(13):2830-2843
pubmed: 35435984
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7624-7631
pubmed: 30936321
Blood. 2022 Dec 22;140(25):2684-2696
pubmed: 35914226
Front Pharmacol. 2015 May 05;6:95
pubmed: 25999859
Cancer Cell. 2015 Jun 8;27(6):769-79
pubmed: 26058076
Front Oncol. 2018 Oct 31;8:488
pubmed: 30430079
J Hematol Oncol. 2018 May 10;11(1):64
pubmed: 29747682
Blood. 2017 Jul 20;130(3):285-296
pubmed: 28539325
Front Immunol. 2018 Nov 28;9:2722
pubmed: 30546360
Am J Hematol. 2017 Sep;92(9):892-901
pubmed: 28543380
Biomark Res. 2022 Apr 25;10(1):24
pubmed: 35468841
J Hematol Oncol. 2019 May 16;12(1):49
pubmed: 31097020
Cell Mol Life Sci. 2015 May;72(9):1715-23
pubmed: 25572297
Cancer Res. 2015 Sep 15;75(18):3853-64
pubmed: 26183927
Blood. 2007 Jun 15;109(12):5136-42
pubmed: 17344466
Front Oncol. 2021 Apr 01;11:627549
pubmed: 33869011
Front Immunol. 2019 Apr 02;10:618
pubmed: 31001252
Proc Natl Acad Sci U S A. 1987 Jan;84(1):204-8
pubmed: 3025855
Cancer Cell. 2015 Jun 8;27(6):755-68
pubmed: 26058075
PLoS One. 2019 Sep 6;14(9):e0222301
pubmed: 31491023
MAbs. 2015;7(2):377-89
pubmed: 25621507
N Engl J Med. 2015 Oct 15;373(16):1541-52
pubmed: 26465987
Leukemia. 2019 Jun;33(6):1324-1336
pubmed: 30552401
Drug Des Devel Ther. 2018 Jan 22;12:195-208
pubmed: 29403265
Br J Haematol. 2022 Sep;198(6):983-987
pubmed: 35607839
Pharmacol Res. 1992 Sep;26 Suppl 2:128-9
pubmed: 1409276
Blood Adv. 2017 Nov 21;1(25):2348-2360
pubmed: 29296885
Expert Opin Biol Ther. 2006 Sep;6(9):943-9
pubmed: 16918261
J Immunol. 1984 Jul;133(1):137-46
pubmed: 6609971
J Allergy Clin Immunol. 2010 Apr;125(4):778-87
pubmed: 20371392
Nat Rev Cancer. 2011 Apr;11(4):254-67
pubmed: 21390059
Mol Cell Proteomics. 2011 May;10(5):M111.007898
pubmed: 21372249
Blood. 2022 Jul 28;140(4):321-334
pubmed: 35500125
Front Oncol. 2020 May 06;10:697
pubmed: 32435621
Leuk Lymphoma. 2014 Oct;55(10):2328-34
pubmed: 24359243
Semin Immunol. 2016 Jun;28(3):309-16
pubmed: 27009480
Cancer Discov. 2020 Apr;10(4):568-587
pubmed: 32086311
J Hematol Oncol. 2021 Oct 9;14(1):162
pubmed: 34627328
Immunology. 2019 May;157(1):3-12
pubmed: 30897205
Nat Immunol. 2011 Jun;12(6):478-84
pubmed: 21739670
Cancer Immunol Res. 2018 Jan;6(1):47-58
pubmed: 29079655
Eur J Cancer. 2010 May;46(7):1271-7
pubmed: 20303742
Front Immunol. 2018 Dec 07;9:2900
pubmed: 30581443
Cancers (Basel). 2022 Jun 11;14(12):
pubmed: 35740552
Blood. 2009 Dec 10;114(25):5136-45
pubmed: 19828704
Blood. 2022 Jul 7;140(1):25-37
pubmed: 35507686
Blood. 2022 Jul 7;140(1):45-57
pubmed: 35452517
PLoS One. 2018 Apr 23;13(4):e0196011
pubmed: 29684048
Oncoimmunology. 2017 Dec 26;7(3):e1407898
pubmed: 29399409
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997304
Mol Ther Oncolytics. 2022 Feb 20;24:719-728
pubmed: 35317521
Nat Genet. 2022 May;54(5):637-648
pubmed: 35513723
Exp Hematol. 2016 Mar;44(3):166-71.e17
pubmed: 26708679
Blood. 2015 Aug 20;126(8):983-92
pubmed: 26056165
Transl Oncol. 2021 Jul;14(7):101079
pubmed: 33862524
Blood. 2011 Sep 29;118(13):3504-11
pubmed: 21715318
Cancer. 2015 Aug 1;121(15):2517-28
pubmed: 25891003
Leukemia. 2016 Mar;30(3):701-7
pubmed: 26526988
Chembiochem. 2022 Aug 17;23(16):e202200092
pubmed: 35466482
Pediatr Dermatol. 2017 Sep;34(5):e265-e270
pubmed: 28884915
Front Immunol. 2021 Jan 28;11:584937
pubmed: 33584650
Leukemia. 2018 Nov;32(11):2307-2315
pubmed: 30315238
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Blood. 2010 Feb 11;115(6):1214-25
pubmed: 19965625
J Exp Med. 2009 Apr 13;206(4):779-91
pubmed: 19349467
Cancer. 2006 Jun 15;106(12):2645-51
pubmed: 16688777
Expert Opin Investig Drugs. 2020 Nov;29(11):1295-1308
pubmed: 32822558
Arch Biochem Biophys. 2012 Oct 15;526(2):146-53
pubmed: 22387378
Int J Mol Sci. 2020 Oct 16;21(20):
pubmed: 33081391
Nat Med. 2001 Nov;7(11):1209-16
pubmed: 11689885
Cell Death Dis. 2012 Nov 15;3:e425
pubmed: 23152061
Biol Blood Marrow Transplant. 2007 Aug;13(8):913-24
pubmed: 17640595
J Hematol Oncol. 2019 Dec 29;12(1):141
pubmed: 31884955
J Leukoc Biol. 2010 Aug;88(2):405-12
pubmed: 20453109
J Immunol. 2001 May 1;166(9):5464-72
pubmed: 11313384
Leukemia. 2019 Sep;33(9):2155-2168
pubmed: 30850736
Acta Haematol. 2005;113(3):181-9
pubmed: 15870488
Immunity. 2009 May;30(5):646-55
pubmed: 19464987
Blood. 2019 Dec 12;134(24):2171-2182
pubmed: 31530562
Haematologica. 2020 Apr;105(4):999-1012
pubmed: 31371417
Blood. 1991 Sep 1;78(5):1173-82
pubmed: 1878584
Blood Cancer J. 2017 Jun 30;7(6):e577
pubmed: 28665419
J Hematol Oncol. 2018 May 2;11(1):60
pubmed: 29716633
Leuk Lymphoma. 1997 Jul;26(3-4):287-98
pubmed: 9322891
J Clin Oncol. 2009 Feb 1;27(4):504-10
pubmed: 19075265
Blood. 1986 Sep;68(3):752-61
pubmed: 3488778
Blood. 2019 May 23;133(21):2291-2304
pubmed: 30796021
Blood. 2017 Oct 26;130(17):1898-1902
pubmed: 28847997
Stem Cell Rev Rep. 2021 Apr;17(2):652-661
pubmed: 33410096
Oncoimmunology. 2017 Nov 20;7(3):e1395127
pubmed: 29375935
Pediatr Blood Cancer. 2009 Dec;53(6):978-83
pubmed: 19637330
Nat Immunol. 2019 Dec;20(12):1584-1593
pubmed: 31745336
Cancer Res. 2002 Jun 1;62(11):3106-12
pubmed: 12036921
Br J Haematol. 2012 Nov;159(3):299-310
pubmed: 22934889
Oncotarget. 2016 Aug 30;7(35):56219-56232
pubmed: 27494836
Front Oncol. 2019 Apr 30;9:316
pubmed: 31338319
Blood. 2016 Jul 28;128(4):473-8
pubmed: 27268088
Leukemia. 2018 Sep;32(9):1970-1983
pubmed: 29483708
Leukemia. 2020 Jan;34(1):35-49
pubmed: 31439943
Clin Immunol. 2006 Sep;120(3):247-59
pubmed: 16797237
Oncogene. 2007 May 28;26(25):3704-13
pubmed: 17530024
Tissue Antigens. 1994 Aug;44(2):73-82
pubmed: 7817381
Curr Opin Hematol. 2013 Jul;20(4):369-73
pubmed: 23695450
Front Immunol. 2017 Jan 20;8:32
pubmed: 28163708
J Clin Invest. 2018 Jul 2;128(7):2802-2818
pubmed: 29781813
EMBO J. 1990 Oct;9(10):3153-62
pubmed: 2120038
Int J Mol Sci. 2016 Mar 29;17(4):461
pubmed: 27043530
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875739
Curr Hematol Malig Rep. 2020 Feb;15(1):9-19
pubmed: 32016790
J Clin Oncol. 2018 Oct 10;36(29):2926-2934
pubmed: 30138085
J Immunol Methods. 2014 May;407:63-75
pubmed: 24704820
Leukemia. 2004 Apr;18(4):703-8
pubmed: 14961034
Nature. 2022 Sep;609(7926):369-374
pubmed: 36045296
Med Oncol. 2005;22(2):191-4
pubmed: 15965283
J Leukoc Biol. 2019 May;105(5):891-904
pubmed: 30676652
Leuk Lymphoma. 2016 May;57(5):1021-32
pubmed: 27050240
Blood. 2004 Dec 1;104(12):3688-96
pubmed: 15292058
Oncotarget. 2017 Nov 22;8(68):112783-112796
pubmed: 29348865
Blood. 2012 Jun 28;119(26):6226-33
pubmed: 22592608
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33597219
Cancer Treat Res. 2019;176:249-268
pubmed: 30596222
Blood. 2006 Oct 15;108(8):2578-86
pubmed: 16825498
J Clin Oncol. 2017 Mar 20;35(9):975-983
pubmed: 28297628
Curr Drug Targets. 2009 Feb;10(2):104-9
pubmed: 19199905
Biomed Res Int. 2014;2014:742831
pubmed: 24689054
Curr Drug Targets. 2021;22(15):1789-1798
pubmed: 33538669
Cancer Res. 2004 Jul 1;64(13):4629-36
pubmed: 15231675
Leukemia. 2020 Jan;34(1):293-295
pubmed: 31435023
Blood. 2018 Apr 5;131(14):1522-1531
pubmed: 29358182
N Engl J Med. 2004 Apr 8;350(15):1535-48
pubmed: 15071128
Leuk Lymphoma. 2022 Dec;63(13):3200-3207
pubmed: 35995457
Blood Cancer J. 2016 May 13;6:e421
pubmed: 27176797
Stem Cell Rev Rep. 2019 Jun;15(3):443-447
pubmed: 30826931
Cancer Biomark. 2016 Mar 18;17(2):117-23
pubmed: 27002769